Johnson & Johnson (JNJ)vsNewGenIvf Group Limited Class A Ordinary Shares (NIVF)
JNJ
Johnson & Johnson
$275.19
+1.53%
HEALTHCARE · Cap: $615.87B
NIVF
NewGenIvf Group Limited Class A Ordinary Shares
$1.20
+4.35%
HEALTHCARE · Cap: $1.25M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 2144577% more annual revenue ($99.33B vs $4.63M). NIVF leads profitability with a 24.2% profit margin vs 16.2%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
NIVF
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$275.19
$131.07 premium
Intrinsic value data unavailable for NIVF.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Reasonable price relative to book value
Every $100 of equity generates 79 in profit
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 24 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
0.0% earnings growth
Smaller company, higher risk/reward
Revenue declined 4.7%
Operating margin of -184.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : NIVF
The strongest argument for NIVF centers on Price/Book, Return on Equity, Debt/Equity. Profitability is solid with margins at 24.2% and operating margin at -184.3%.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : NIVF
The primary concerns for NIVF are EPS Growth, Market Cap, Revenue Growth.
Key Dynamics to Monitor
JNJ profiles as a mature stock while NIVF is a declining play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.21 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JNJ scores higher overall (57/100 vs 34/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →NewGenIvf Group Limited Class A Ordinary Shares
HEALTHCARE · MEDICAL CARE FACILITIES · USA
NewGenIvf Group Limited (NIVF) is a pioneering organization in the reproductive health industry, specializing in innovative fertility solutions, including advanced in vitro fertilization (IVF) services. The company is dedicated to enhancing success rates in assisted reproductive technologies and is strategically positioned to capitalize on the growing global demand for fertility treatments, supported by a robust network of clinics and strategic partnerships. As the fertility services market continues to expand, NIVF is well-equipped for substantial growth, with a mission to assist individuals and couples in their journey to parenthood through forward-thinking healthcare solutions.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?